DE69233612T2 - Verfahren zur bildung einer strukturellen und funktionellen diversität in einer peptidsequenz - Google Patents

Verfahren zur bildung einer strukturellen und funktionellen diversität in einer peptidsequenz Download PDF

Info

Publication number
DE69233612T2
DE69233612T2 DE69233612T DE69233612T DE69233612T2 DE 69233612 T2 DE69233612 T2 DE 69233612T2 DE 69233612 T DE69233612 T DE 69233612T DE 69233612 T DE69233612 T DE 69233612T DE 69233612 T2 DE69233612 T2 DE 69233612T2
Authority
DE
Germany
Prior art keywords
rag
vectors
genes
peptide sequence
recombination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69233612T
Other languages
German (de)
English (en)
Other versions
DE69233612D1 (de
Inventor
Sacha Kallenbach
Noëlle DOYEN
Francois Rougeon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur
Original Assignee
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur filed Critical Institut Pasteur
Application granted granted Critical
Publication of DE69233612D1 publication Critical patent/DE69233612D1/de
Publication of DE69233612T2 publication Critical patent/DE69233612T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C12N15/1024—In vivo mutagenesis using high mutation rate "mutator" host strains by inserting genetic material, e.g. encoding an error prone polymerase, disrupting a gene for mismatch repair
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1264—DNA nucleotidylexotransferase (2.7.7.31), i.e. terminal nucleotidyl transferase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69233612T 1991-12-11 1992-12-11 Verfahren zur bildung einer strukturellen und funktionellen diversität in einer peptidsequenz Expired - Fee Related DE69233612T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9115389 1991-12-11
FR9115389A FR2685004A1 (fr) 1991-12-11 1991-12-11 Procede de generation d'une diversite structurale et fonctionnelle dans une sequence peptidique.
PCT/FR1992/001178 WO1993012228A1 (fr) 1991-12-11 1992-12-11 Procede de generation d'une diversite structurale et fonctionnelle dans une sequence peptidique

Publications (2)

Publication Number Publication Date
DE69233612D1 DE69233612D1 (de) 2006-05-18
DE69233612T2 true DE69233612T2 (de) 2007-07-05

Family

ID=9419935

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69233612T Expired - Fee Related DE69233612T2 (de) 1991-12-11 1992-12-11 Verfahren zur bildung einer strukturellen und funktionellen diversität in einer peptidsequenz

Country Status (11)

Country Link
US (1) US5756323A (https=)
EP (1) EP0618965B1 (https=)
JP (1) JPH07504086A (https=)
AT (1) ATE322543T1 (https=)
CA (1) CA2125192A1 (https=)
DE (1) DE69233612T2 (https=)
DK (1) DK0618965T3 (https=)
ES (1) ES2260753T3 (https=)
FR (1) FR2685004A1 (https=)
PT (1) PT618965E (https=)
WO (1) WO1993012228A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
DK1036198T3 (da) 1997-12-08 2013-01-02 California Inst Of Techn Fremgangsmåde til fremstilling af polynukleotid- og polypeptidsekvenser
US7122339B2 (en) 1998-10-09 2006-10-17 Medical Research Council Method for generating diversity
DK1117774T3 (da) * 1998-10-09 2010-05-03 Medical Res Council Fremgangsmåde til diversitetsgenerering
EP1010763A1 (en) * 1998-12-11 2000-06-21 Institut Pasteur Enhanced expression of heterologous proteins in recombinant bacteria through reduced growth temperature and co-expression of rare tRNA's
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
WO2005007823A2 (en) * 2003-07-11 2005-01-27 New York University Compositions, kits, and methods for stimulation of homologous recombination
BRPI0807952A2 (pt) 2007-02-20 2014-06-10 Anaptysbio Inc Sistemas de hipermutação somática
WO2009129247A2 (en) * 2008-04-14 2009-10-22 Innovative Targeting Solutions Inc. Sequence diversity generation in immunoglobulins
EP2412806B1 (en) 2010-07-28 2014-01-08 Institut Pasteur Use of terminal deoxynucleotidyl transferase for mutagenic DNA repair to generate variability, at a determined position in DNA
EP2825653A4 (en) 2012-03-14 2016-01-20 Innovative Targeting Solutions Inc PRODUCTION OF TARGETED SEQUENCE DIVERSITY IN FUSION PROTEINS
WO2013134880A1 (en) 2012-03-14 2013-09-19 Innovative Targeting Solutions Inc. Generating targeted sequence diversity in proteins

Also Published As

Publication number Publication date
WO1993012228A1 (fr) 1993-06-24
PT618965E (pt) 2006-08-31
JPH07504086A (ja) 1995-05-11
ES2260753T3 (es) 2006-11-01
EP0618965B1 (fr) 2006-04-05
DE69233612D1 (de) 2006-05-18
EP0618965A1 (fr) 1994-10-12
FR2685004B1 (https=) 1995-01-06
CA2125192A1 (fr) 1993-06-24
ATE322543T1 (de) 2006-04-15
FR2685004A1 (fr) 1993-06-18
DK0618965T3 (da) 2006-08-14
US5756323A (en) 1998-05-26

Similar Documents

Publication Publication Date Title
DE3153606C2 (https=)
DE60012559T2 (de) Polypeptide mit nicht natürlichen primären signalmotiven
DE69332859T2 (de) Konsensus-kozak-sequenzen zur säugetier-exprimierung
DE3546806C2 (https=)
DE69532801T2 (de) Rekombinanter Bakulovirus und seine Verwendung zur Herstellung monoklonaler Antikörper
DE3043981C2 (https=)
DE3485869T2 (de) Herstellung heterodimerer menschlicher fruchtbarkeitshormone.
DE3486179T2 (de) Verfahren zur herstellung vielkettige polypeptide oder proteine.
DE69030579T2 (de) Verfahren zur herstellung von fusionsproteinen
DE3486216T2 (de) Hybrid-DNS-Synthesis von reifen insulinähnlichen Wachstumsfaktoren.
DE3486474T2 (de) Produkte und Methoden für die Herstellung einer heterodimerer menschlicher LH mit einem Met42 Val55 alpha Untereinheit
DE69032743T2 (de) Herstellung von fusionsproteinen
DE68910354T2 (de) Menschliches mutantes Angiogenin (Angiogenese-Faktor mit überlegener Angiogenin-Aktivität), Gene dafür und Methode zur Expression.
DE69233612T2 (de) Verfahren zur bildung einer strukturellen und funktionellen diversität in einer peptidsequenz
DE3382575T2 (de) Dna-sequenzen, rekombinante dna-molekuele und verfahren zur herstellung von schweinewachstumshormonaehnlichen polypeptiden.
WO1998054225A2 (de) Human-cd28 spezifische monoklonale antikörper zur antigenunspezifischen aktivierung von t-lymphozyten
DD210071A5 (de) Verfahren zur herstellung einer lebensfaehigen kultur
DD209652A5 (de) Verfahren zur herstellung eines replikablen vektors
DE69432901T2 (de) Expressionssystem von antikörpern bei homologischer rekombinierung in murinezellen
DE3752158T2 (de) Molekulare Klonierung und Expression von menschlichem IL-3
DD202046A5 (de) Verfahren zur herstellung eines chimeren proteins
CH675731A5 (https=)
DE3485923T2 (de) Dna-gen, verfahren zu seiner herstellung und dieses gen enthaltendes plasmid.
DE3586830T2 (de) Verfahren zur ligation von heterogenen genen.
DE3688870T2 (de) Dns-sequenz.

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee